Bayer's Pipeline Wins and Berenberg's Raised Target: What's Really Driving the Stock
Published on 11/19/2026 at 13:17 | Editorial boerse-global.deBerenberg has raised its price target on Bayer from EUR 53.50 to EUR 62.00 while keeping its "Hold" rating, citing a strong year for the German life-sciences group and pointing to several forces behind the shares' recent relative strength. In a study published Tuesday, analyst Sebastian Bray attributed part of that outperformance to rotation out of technology stocks and into healthcare and defensive names, while also flagging pharma momentum and progress in glyphosate litigation as potential share-price drivers.
The stock slipped 0.5% yesterday, though it was up 0.4% today and trading 3.2% below its 52-week high. The relative strength Berenberg describes refers to the recent trend rather than the latest session.
A Spinoff Option Held in Reserve
Bray also raised the possibility of a later separation of Monsanto, including a stock-market listing. By the end of the decade, in his assessment, Bayer could plough the proceeds into pharmaceutical development.
Should investors sell immediately? Or is it worth buying Bayer?
Two Regulatory Green Lights
The upgraded target follows a pair of approvals on either side of the world. Late last week the US Food and Drug Administration cleared asundexian under the brand name Sunharbo to reduce the risk of further strokes in certain adults, used in combination with an antiplatelet therapy. Bayer described the drug as the world's first approved factor XIa inhibitor.
At the start of November, China's NMPA also approved sevabertinib as a first-line treatment for adults with HER2-mutant non-small cell lung cancer.
Third-Quarter Figures and a Brighter Outlook
Bayer reported third-quarter 2026 revenue of EUR 10.1 billion and EBITDA before special items of EUR 1.62 billion. Alongside those numbers, the group lifted its guidance for the pharma division's margin, for group EBITDA before special items and for free cash flow.
Ad
Bayer Stock: New Analysis - 19 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
